Ocular surface disease is common in moderate-to-severe atopic dermatitis patients

Note: Funding Information: Roselie E. Achten has nothing to disclose. Daphne S. Bakker is a speaker for Sanofi Genzyme and LEO Pharma. Chantal M. van Luijk is a speaker for Sanofi Genzyme and Santen. Marlot van der Wal has nothing to disclose. Marlies de Graaf is a principal investigator and advisory board member and/or speaker for Sanofi Genzyme and Regeneron Pharmaceuticals and LEO Pharma. Femke van Wijk is a speaker and/or consultant for Janssen, Johnson & Johnson and Takeda. Nicolaas P.A. Zuithoff has nothing to disclose. Lisa P. van der Rijst has nothing to disclose. Celeste M. Boesjes has nothing to disclose. Judith L. Thijs is a speaker for Sanofi Genzyme and LEO Pharma. Joke H. de Boer received research funding from Abbvie; this is outside the submitted work. Marjolein S. de Bruin‐Weller is a consultant, advisory board member and/or speaker for AbbVie, Almirall, Aslan, Arena, Eli Lilly, Galderma, Janssen, Leo Pharma, Pfizer, Regeneron and Sanofi‐Genzyme.